Background: R/R B-NHL patients with disease progression after CAR-T therapy have poor prognosis and no standard chemotherapy regimen has been defined. We aimed to explore whether receiving allo-HSCT could improve the outcomes of R/R B-NHL patients who have disease progression after CAR-T therapy.Methods: From October 2017 to June 2021, we retrospectively report outcomes of R/R B-NHL patients with disease progression after CAR-T cell treatment, then receiving allo-HSCT. Results: Among 9 patients, 4 were males and 5 females, with a median age of 44 (27-52) years. 5 patients were diagnosed refractory/relapsed diffuse large B cell lymphoma, 1 patient was Burkitt lymphoma, 1 was B lymphoblastic lymphoma, 1 was transformed DLBCL and 1 was gray zone lymphoma. 8/9 donors were haploidentical family member, 1/9 donor was identical sibling. The median time from CAR-T treatment to transplantation was 2.3 (1.0-12.3) months. 9/9 patients obtained complete engraftment. The median time of neutrophil implantation was 12 (11- 19) days, and 13 (9-20) days of platelet implantation. The median follow-up was 7.9 (3.4-48.6) months. 4/9 patients received CR and 1/9 patient received PR during the follow up. The objective response rate (ORR) was 55.6%. The six-months overall survivaln (OS) and progression-free survival (PFS) were 66.7% and 33.3%, respectively. 1 case experienced acute graft-versus-host disease(aGVHD)grade Ⅱ, 1 case with aGVHD grade Ⅲ. Among 5 survivals, localized chronic GVHD occurred in 1 patient. During the follow up, four patients have died and the causes were disease relapses and progressions (2 patients), acute renal failure (1 patient), severe pulmonary infection (1 patient). No-relapse mortality was 22.2%.Conclusion: The present study demonstrated that allo- HSCT is a feasible and safe choice with favorable outcome for R/R B-NHL patients with disease progression after CAR-T therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.